Semaglutide has been approved by the FDA for the treatment of type 2 diabetes at a dose of 1mg per week
Slide from Katherine Tuttles presentation, during FLOW session, 61st European Renal Association Congress Conclusion The FLOW trial showed that semaglutide significantly decreased the risk of progression of kidney disease in T2DM, without significant increases in serious adverse events
Wear breathable fabrics, maintain a cool environment, and avoid known triggers such as caffeine or spicy foods
Medication interactions : Certain medications can interfere with weight loss efforts, including some antidepressants (particularly paroxetine, mirtazapine), antipsychotics (especially olanzapine, quetiapine), mood stabilizers (valproate), antiepileptics (gabapentin, pregabalin), corticosteroids, beta-blockers, and diabetes medications (insulin, sulfonylureas)
This ensures that the medication is safe and suitable for you to take and that you satisfy the eligibility criteria